NFL Biosciences SA (EPA:ALNFL)

France · Delayed Price · Currency is EUR

0.8650

-0.0130 (-1.48%)

Jun 23, 2026, 5:35 PM CET

-24.12% (1Y)

Market Cap	10.96M -25.3%
Revenue (ttm)	188.00 +308.7%
Net Income	-3.32M
EPS	-0.26
Shares Out	12.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,782
Open	0.9190
Previous Close	0.8780
Day's Range	0.8500 - 0.9190
52-Week Range	0.8000 - 1.8460
Beta	1.14
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 22, 2026

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company’s pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. NFL Biosciences SA was incorporated in 2006 and... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2006

Employees 4

Stock Exchange Euronext Paris

Ticker Symbol ALNFL

Full Company Profile

Financial Performance

In 2025, NFL Biosciences's revenue was 188, an increase of 308.70% compared to the previous year's 46. Losses were -3.32 million, 59.5% more than in 2024.

Financial Statements